This research has analyzed the effectiveness of stem cell therapies in managing multiple sclerosis (MS), comparing them to non-stem cell treatments.
This study examined clinical trial data from ten studies, covering a sample size of 5,288 patients, to evaluate the impact of autologous hematopoietic stem cell transplantation (AHSCT) and mesenchymal stem cells (MSCs).
Findings indicate that human umbilical cord-derived MSCs (hUC-MSCs) were associated with reductions in the Annualized Relapse Rate (SUCRA: 70.9%) and improvements in the Expanded Disability Status Scale (SUCRA: 77.1%). Additionally, AHSCT was linked to a lower mortality rate (SUCRA: 69.8%), while autologous peripheral blood stem cell transplantation (APBSCT) demonstrated a reduction in recurrence rate (SUCRA: 86.7%) and improvement in No Evidence of Disease Activity-3 (NEDA-3) scores (SUCRA: 92.8%).
These findings suggest that stem cell therapies have the potential to play a meaningful role in MS treatment, particularly in reducing relapse rates and improving neurological function.
